{"url":"https://lda.senate.gov/api/v1/filings/4108d8a3-2c60-4ba2-b320-039ff81c72d5/?format=json","filing_uuid":"4108d8a3-2c60-4ba2-b320-039ff81c72d5","filing_type":"YY","filing_type_display":"Year-End Report","filing_year":2007,"filing_period":"year_end","filing_period_display":"Year-End (July 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/4108d8a3-2c60-4ba2-b320-039ff81c72d5/print/","filing_document_content_type":"application/pdf","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":null,"dt_posted":"2008-02-06T14:33:15.370000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":null,"registrant_address_2":null,"registrant_different_address":null,"registrant_city":null,"registrant_state":null,"registrant_zip":null,"registrant":{"id":4117,"url":"https://lda.senate.gov/api/v1/registrants/4117/?format=json","house_registrant_id":30920,"name":"APCO WORLDWIDE LLC","description":"Public relations and strategic communications","address_1":"1299 Pennsylvania Avenue, NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JONATHAN A. FRIEDMAN","contact_telephone":"+1 202-778-1000","dt_updated":"2026-01-06T13:39:00.722129-05:00"},"client":{"id":103910,"url":"https://lda.senate.gov/api/v1/clients/103910/?format=json","client_id":1002690,"name":"ZYMOGENETICS","general_description":"Biotechnology/ pharmaceutical company","client_government_entity":false,"client_self_select":false,"state":null,"state_display":null,"country":"","country_display":"* Undetermined","ppb_state":null,"ppb_state_display":null,"ppb_country":"","ppb_country_display":"* Undetermined","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Follow-on biologics","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":17083,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"JOHNSTON","suffix":null,"suffix_display":null},"covered_position":"N/A","new":null}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Patent reform","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":17083,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"JOHNSTON","suffix":null,"suffix_display":null},"covered_position":"N/A","new":null}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}